40
IRUS Total
Downloads

Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

Title: Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study
Authors: Fendler, A
Au, L
Shepherd, STC
Byrne, F
Cerrone, M
Boos, LA
Rzeniewicz, K
Gordon, W
Shum, B
Gerard, CL
Ward, B
Xie, W
Schmitt, AM
Joharatnam-Hogan, N
Cornish, GH
Pule, M
Mekkaoui, L
Ng, KW
Carlyle, E
Edmonds, K
Del Rosario, L
Sarker, S
Lingard, K
Mangwende, M
Holt, L
Ahmod, H
Stone, R
Gomes, C
Flynn, HR
Agua-Doce, A
Hobson, P
Caidan, S
Howell, M
Wu, M
Goldstone, R
Crawford, M
Cubitt, L
Patel, H
Gavrielides, M
Nye, E
Snijders, AP
MacRae, J
Nicod, J
Gronthoud, F
Shea, RL
Messiou, C
Cunningham, D
Chau, I
Starling, N
Turner, N
Welsh, L
Van As, N
Jones, RL
Droney, J
Banerjee, S
Tatham, KC
Jhanji, S
O'Brien, M
Curtis, O
Harrington, K
Bhide, S
Bazin, J
Robinson, A
Stephenson, C
Slattery, T
Khan, Y
Tippu, Z
Leslie, I
Gennatas, S
Okines, A
Reid, A
Young, K
Furness, AJS
Pickering, L
Gandhi, S
Gamblin, S
Swanton, C
Nicholson, E
Kumar, S
Yousaf, N
Wilkinson, KA
Swerdlow, A
Harvey, R
Kassiotis, G
Larkin, J
Wilkinson, RJ
Turajlic, S
Item Type: Journal Article
Abstract: Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4+ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment specific, but presented compensatory cellular responses, further supported by clinical recovery in all but one patient. Overall, these findings advance the understanding of the nature and duration of the immune response to SARS-CoV-2 in patients with cancer.
Issue Date: 27-Oct-2021
Date of Acceptance: 17-Sep-2021
URI: http://hdl.handle.net/10044/1/92957
DOI: 10.1038/s43018-021-00275-9
ISSN: 2662-1347
Publisher: Nature Research
Start Page: 1321
End Page: 1337
Journal / Book Title: Nature Cancer
Volume: 2
Copyright Statement: © The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Sponsor/Funder: Wellcome Trust
Funder's Grant Number: WDAI_P83556
Keywords: Science & Technology
Life Sciences & Biomedicine
Oncology
CORONAVIRUS DISEASE 2019
COVID-19
MORTALITY
SEROCONVERSION
SEVERITY
IMPACT
Science & Technology
Life Sciences & Biomedicine
Oncology
CORONAVIRUS DISEASE 2019
COVID-19
MORTALITY
SEROCONVERSION
SEVERITY
IMPACT
Publication Status: Published
Online Publication Date: 2021-10-27
Appears in Collections:Department of Surgery and Cancer
Department of Infectious Diseases
Faculty of Medicine
Imperial College London COVID-19



This item is licensed under a Creative Commons License Creative Commons